Columbus Circle Investors Lowers stake in DexCom (DXCM)

DexCom (DXCM) : Columbus Circle Investors reduced its stake in DexCom by 6.16% during the most recent quarter end. The investment management company now holds a total of 1,696,313 shares of DexCom which is valued at $154,143,962 after selling 111,357 shares in DexCom , the firm said in a disclosure report filed with the SEC on Aug 2, 2016.DexCom makes up approximately 1.48% of Columbus Circle Investors’s portfolio.

Other Hedge Funds, Including , Spot Trading L.l.c boosted its stake in DXCM in the latest quarter, The investment management firm added 14,707 additional shares and now holds a total of 14,784 shares of DexCom which is valued at $1,343,422. DexCom makes up approx 0.18% of Spot Trading L.l.c’s portfolio.Rhenman Partners Asset Management Ab reduced its stake in DXCM by selling 20,000 shares or 26.67% in the most recent quarter. The Hedge Fund company now holds 55,000 shares of DXCM which is valued at $4,997,850. DexCom makes up approx 0.80% of Rhenman Partners Asset Management Ab’s portfolio.Gilder Gagnon Howe Co reduced its stake in DXCM by selling 21,073 shares or 2.61% in the most recent quarter. The Hedge Fund company now holds 786,047 shares of DXCM which is valued at $71,428,091. DexCom makes up approx 1.32% of Gilder Gagnon Howe Co’s portfolio.Shaker Investmentsoh boosted its stake in DXCM in the latest quarter, The investment management firm added 11,000 additional shares and now holds a total of 79,145 shares of DexCom which is valued at $6,188,348. DexCom makes up approx 5.49% of Shaker Investmentsoh’s portfolio.

DexCom closed down -0.57 points or -0.62% at $90.66 with 8,04,412 shares getting traded on Monday. Post opening the session at $91.25, the shares hit an intraday low of $90.48 and an intraday high of $91.72 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, DexCom reported $-0.24 EPS for the quarter, missing the analyst consensus estimate by $ -0.12 based on the information available during the earnings call on Aug 2, 2016. Analyst had a consensus of $-0.12. The company had revenue of $137.30 million for the quarter, compared to analysts expectations of $132.54 million. The company’s revenue was up 47.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.05 EPS.

Many Wall Street Analysts have commented on DexCom. Company shares were Reiterated by The Benchmark Company on Aug 3, 2016 to “Buy”, Firm has raised the Price Target to $ 106 from a previous price target of $86 .

Dexcom Inc. (Dexcom) is a medical device company. The Company is focused on the design development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products consist of DexCom G4 DexCom G4 PLATINUM and DexCom Share System. The DexCom G4 PLATINUM with Share uses a wireless connection between a patient’s receiver and an application on the patient’s iPhone to transmit glucose information to applications on the mobile devices of up to five designated recipients or followers who can remotely monitor a patient’s glucose information and receive alert notifications anywhere they have an Internet connection. SweetSpot’s data transfer service is a Medical Device Data System (MDDS) and allows researchers to control the transfer of data from certain diabetes devices to research tools and databases according to their own research workflows.

Leave a Reply

DexCom - Is it time to Sell?

Top Brokerage Firms are advising their investors on DexCom. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.